PMID- 30303616 OWN - NLM STAT- MEDLINE DCOM- 20190118 LR - 20190118 IS - 1476-4431 (Electronic) IS - 1476-4431 (Linking) VI - 28 IP - 6 DP - 2018 Nov TI - A pilot study documenting increased thrombin generation following abrupt withdrawal of heparin therapy in healthy dogs. PG - 518-526 LID - 10.1111/vec.12778 [doi] AB - OBJECTIVE: To document if a transient hypercoagulable state occurs in healthy dogs following abrupt cessation of unfractionated heparin (UFH) therapy. DESIGN: Prospective experimental pilot study. SETTING: University research facility. ANIMALS: Seven adult random-source male dogs. INTERVENTION: Thromboelastography (TEG) and thrombin-antithrombin (TAT) complex formation were used to assess coagulation status in healthy dogs. Seven adult research dogs received 200-300 IU/kg subcutaneous UFH every 8 hours for 4 days. A final IV bolus of 100 IU/kg was given on day 4 and the peak measured heparin concentration 1 hour later is defined as the start of heparin withdrawal (time 0). Citrated whole blood samples were collected at baseline (prior to heparin administration) and 3, 6, 12, 30, and 48 hours after UFH withdrawal. At all time points, a kaolin-activated TEG was performed and citrated plasma for measurement of TAT concentration was collected for batch analysis. Fibrinogen concentration, PCV, total plasma proteins, and platelet count were measured at baseline and 48 hours after heparin withdrawal. MEASUREMENTS AND MAIN RESULTS: Compared to baseline, TAT was increased 12 hours after heparin withdrawal and returned to baseline by 30 hours. TEG clot formation time (K) was decreased 30 and 48 hours after heparin withdrawal. CONCLUSION: TAT results suggest that a transient increase in thrombin generation developed 12 hours after withdrawal of UFH therapy. Though clot kinetics were rapid compared to baseline beginning 30 hours after heparin withdrawal, a return to baseline was not documented. Future studies are warranted to determine the clinical relevance of these results and to evaluate the effect of UFH withdrawal in critically ill animals. CI - (c) Veterinary Emergency and Critical Care Society 2018. FAU - Mays, Erin M AU - Mays EM AUID- ORCID: 0000-0002-7088-6375 AD - Departments of Clinical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27695 (Mays, Daorman, Hanel), and. FAU - Dorman, David C AU - Dorman DC AD - Departments of Clinical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27695 (Mays, Daorman, Hanel), and. FAU - McKendry, Colleen AU - McKendry C AD - Department of Statistics, NCSU Bioinformatics Research Center, NCSU College of Physical and Mathematical Sciences, Raleigh, NC, 27607 (McKendry). FAU - Hanel, Rita M AU - Hanel RM AUID- ORCID: 0000-0002-2814-1003 AD - Departments of Clinical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27695 (Mays, Daorman, Hanel), and. LA - eng PT - Clinical Trial, Veterinary PT - Journal Article DEP - 20181010 PL - United States TA - J Vet Emerg Crit Care (San Antonio) JT - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) JID - 101152804 RN - 0 (Anticoagulants) RN - 9005-49-6 (Heparin) RN - EC 3.4.21.5 (Thrombin) SB - IM MH - Animals MH - Anticoagulants/administration & dosage/*pharmacology MH - Dogs MH - Heparin/administration & dosage/*pharmacology MH - Infusions, Intravenous/veterinary MH - Male MH - Pilot Projects MH - Prospective Studies MH - Thrombelastography/veterinary MH - Thrombin/biosynthesis/*drug effects OTO - NOTNLM OT - hypercoagulable OT - rebound OT - thromboelastography EDAT- 2018/10/12 06:00 MHDA- 2019/01/19 06:00 CRDT- 2018/10/11 06:00 PHST- 2016/11/22 00:00 [received] PHST- 2017/04/12 00:00 [revised] PHST- 2017/05/24 00:00 [accepted] PHST- 2018/10/12 06:00 [pubmed] PHST- 2019/01/19 06:00 [medline] PHST- 2018/10/11 06:00 [entrez] AID - 10.1111/vec.12778 [doi] PST - ppublish SO - J Vet Emerg Crit Care (San Antonio). 2018 Nov;28(6):518-526. doi: 10.1111/vec.12778. Epub 2018 Oct 10.